Declared bankruptcy in Feb 2023
CLVS - Clovis Oncology, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boulder,
United States
Type: Equity
CLVS price evolution
CLVS
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $58.32 | $94.58 | $122.24 | $143.43 |
| Short term investments | ||||
| Net receivables | $19.45 | $18.57 | $27.3 | $26.87 |
| Inventory | $103.05 | $107.31 | $120.62 | $123.54 |
| Total current assets | $102.21 | $142.28 | $185.53 | $198.09 |
| Long term investments | ||||
| Property, plant & equipment | $21.52 | $23.15 | $24.66 | $25.66 |
| Goodwill & intangible assets | $119.42 | $120.76 | $122.1 | $123.44 |
| Total noncurrent assets | $244.57 | $250.57 | $265.99 | $274.75 |
| Total investments | ||||
| Total assets | $346.77 | $392.86 | $451.53 | $472.83 |
| Current liabilities | ||||
| Accounts payable | $18.12 | $24.23 | $22.33 | $27.31 |
| Deferred revenue | ||||
| Short long term debt | $663.83 | $29.11 | $20.56 | $11.91 |
| Total current liabilities | $747.87 | $121.27 | $121.83 | $125.21 |
| Long term debt | $16.79 | $639.28 | $633 | $626.46 |
| Total noncurrent liabilities | $16.79 | $639.28 | $633 | $626.46 |
| Total debt | $680.62 | $668.38 | $653.56 | $638.37 |
| Total liabilities | $764.66 | $760.55 | $754.84 | $751.67 |
| Shareholders' equity | ||||
| Retained earnings | -$3064.77 | -$3008.75 | -$2937.42 | -$2877.25 |
| Other shareholder equity | -$40.91 | -$41.84 | -$42.99 | -$43.43 |
| Total shareholder equity | -$417.89 | -$367.69 | -$303.31 | -$278.84 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $143.43 | $240.23 | $161.83 | $221.88 |
| Short term investments | $134.83 | $298.27 | ||
| Net receivables | $26.87 | $26.51 | $20.56 | $12.89 |
| Inventory | $123.54 | $134.84 | $124.57 | $140.98 |
| Total current assets | $198.09 | $310.83 | $366.47 | $572.3 |
| Long term investments | ||||
| Property, plant & equipment | $25.66 | $42.52 | $43.43 | $26.52 |
| Goodwill & intangible assets | $123.44 | $128.82 | $125.99 | $115 |
| Total noncurrent assets | $274.75 | $294.73 | $303.14 | $291.26 |
| Total investments | $134.83 | $298.27 | ||
| Total assets | $472.83 | $605.55 | $669.6 | $863.56 |
| Current liabilities | ||||
| Accounts payable | $27.31 | $26.69 | $32.24 | $28.52 |
| Deferred revenue | ||||
| Short long term debt | $11.91 | $69.53 | $5.41 | |
| Total current liabilities | $125.21 | $184.93 | $133.08 | $125.75 |
| Long term debt | $626.46 | $577.4 | $709.22 | $575.47 |
| Total noncurrent liabilities | $626.46 | $579.37 | $710.78 | $591.34 |
| Total debt | $638.37 | $646.93 | $714.63 | $575.47 |
| Total liabilities | $751.67 | $764.3 | $843.86 | $717.09 |
| Shareholders' equity | ||||
| Retained earnings | -$2877.25 | -$2612.73 | -$2243.51 | -$1843.09 |
| Other shareholder equity | -$43.43 | -$44.3 | -$44.87 | -$44.63 |
| Total shareholder equity | -$278.84 | -$158.75 | -$174.26 | $146.47 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $30.66 | $32.14 | $34.25 | $35.97 |
| Cost of revenue | $8.61 | $9.21 | $9.41 | $9.73 |
| Gross Profit | $22.05 | $22.93 | $24.83 | $26.24 |
| Operating activities | ||||
| Research & development | $30.79 | $36.43 | $42.25 | $41.82 |
| Selling, general & administrative | $30.38 | $32.59 | $29.21 | $33.34 |
| Total operating expenses | $66.29 | $82.31 | $75.19 | $78.95 |
| Operating income | -$44.23 | -$59.38 | -$50.36 | -$52.71 |
| Income from continuing operations | ||||
| EBIT | -$46.12 | -$61.7 | -$51.19 | -$56.16 |
| Income tax expense | $0.04 | -$0.04 | -$0.12 | -$0.28 |
| Interest expense | $9.86 | $9.67 | $9.1 | $8.51 |
| Net income | ||||
| Net income | -$56.01 | -$71.33 | -$60.17 | -$64.39 |
| Income (for common shares) | -$56.01 | -$71.33 | -$60.17 | -$64.39 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $148.76 | $164.52 | $143.01 | $95.39 |
| Cost of revenue | $38.83 | $41.3 | $34.69 | $22.07 |
| Gross Profit | $109.93 | $123.22 | $108.32 | $73.31 |
| Operating activities | ||||
| Research & development | $186.6 | $257.71 | $283.15 | $231.35 |
| Selling, general & administrative | $128.4 | $163.89 | $182.77 | $175.78 |
| Total operating expenses | $335.7 | $425.4 | $485.07 | $407.13 |
| Operating income | -$225.77 | -$302.19 | -$376.75 | -$333.81 |
| Income from continuing operations | ||||
| EBIT | -$230.82 | -$339.25 | -$379.22 | -$354.22 |
| Income tax expense | -$0.4 | -$0.55 | $1.8 | $0.61 |
| Interest expense | $34.1 | $30.51 | $19.41 | $13.18 |
| Net income | ||||
| Net income | -$264.52 | -$369.21 | -$400.42 | -$368.01 |
| Income (for common shares) | -$264.52 | -$369.21 | -$400.42 | -$368.01 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$56.01 | -$71.33 | -$60.17 | -$64.39 |
| Operating activities | ||||
| Depreciation | $1.89 | $1.9 | $1.92 | $2 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.89 | $5.4 | $6.63 | $7.05 |
| Total cash flows from operations | -$40.61 | -$35.13 | -$58.49 | -$41.34 |
| Investing activities | ||||
| Capital expenditures | -$0.09 | -$0.05 | -$0.06 | -$0.07 |
| Investments | ||||
| Total cash flows from investing | -$0.09 | -$0.05 | -$0.06 | -$0.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.38 | $28.64 | $3.44 | |
| Net borrowings | $6.18 | $8.76 | $9.22 | $9.73 |
| Total cash flows from financing | $6.18 | $9.14 | $37.86 | $13.17 |
| Effect of exchange rate | -$1.74 | -$1.63 | -$0.49 | -$0.28 |
| Change in cash and equivalents | -$36.26 | -$27.66 | -$21.19 | -$28.52 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$264.52 | -$369.21 | -$400.42 | -$368.01 |
| Operating activities | ||||
| Depreciation | $8.5 | $8.2 | $7.77 | $4.6 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.45 | $50.79 | $54.3 | $49.09 |
| Total cash flows from operations | -$196.06 | -$252.73 | -$323.62 | -$366 |
| Investing activities | ||||
| Capital expenditures | -$0.31 | -$0.35 | -$3.02 | -$9.24 |
| Investments | $134.68 | $162.16 | -$200 | |
| Total cash flows from investing | -$0.31 | $126.33 | $143.4 | -$264.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $118.11 | $248.03 | $3.27 | $97.86 |
| Net borrowings | -$17.95 | -$44.39 | $116.62 | $290.61 |
| Total cash flows from financing | $100.16 | $203.64 | $119.89 | $388.46 |
| Effect of exchange rate | -$0.59 | $1.15 | $0.29 | -$0.55 |
| Change in cash and equivalents | -$96.8 | $78.4 | -$60.04 | -$242.32 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 144.80M |
| Revenue | $133.02M |
|---|---|
| EBITDA | -$207.45M |
| EBIT | -$215.16M |
| Net Income | -$251.91M |
| Revenue Q/Q | -19.13% |
| Revenue Y/Y | -14.78% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -2.60 |
| Cash/Share | 0.40 |
| EPS | -$1.74 |
|---|---|
| ROA | -60.55% |
| ROE | 73.67% |
| Debt/Equity | -2.70 |
|---|---|
| Net debt/EBITDA | -3.40 |
| Current ratio | 0.14 |
| Quick ratio | -0.00 |